5-139480847-C-T
Position:
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PM1PM2PP5_Very_Strong
The ENST00000330794.9(STING1):c.463G>A(p.Val155Met) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000031 in 1,614,002 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Genomes: 𝑓 0.000026 ( 0 hom., cov: 32)
Exomes 𝑓: 6.8e-7 ( 0 hom. )
Consequence
STING1
ENST00000330794.9 missense
ENST00000330794.9 missense
Scores
3
10
6
Clinical Significance
Conservation
PhyloP100: 2.64
Genes affected
STING1 (HGNC:27962): (stimulator of interferon response cGAMP interactor 1) This gene encodes a five transmembrane protein that functions as a major regulator of the innate immune response to viral and bacterial infections. The encoded protein is a pattern recognition receptor that detects cytosolic nucleic acids and transmits signals that activate type I interferon responses. The encoded protein has also been shown to play a role in apoptotic signaling by associating with type II major histocompatibility complex. Mutations in this gene are the cause of infantile-onset STING-associated vasculopathy. Alternate splicing results in multiple transcript variants. [provided by RefSeq, Sep 2014]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 12 ACMG points.
PM1
In a hotspot region, there are 3 aminoacids with missense pathogenic changes in the window of +-8 aminoacids around while only 0 benign, 2 uncertain in ENST00000330794.9
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 5-139480847-C-T is Pathogenic according to our data. Variant chr5-139480847-C-T is described in ClinVar as [Pathogenic]. Clinvar id is 143862.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr5-139480847-C-T is described in UniProt as null. Variant chr5-139480847-C-T is described in UniProt as null. Variant chr5-139480847-C-T is described in UniProt as null.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
STING1 | NM_198282.4 | c.463G>A | p.Val155Met | missense_variant | 5/8 | ENST00000330794.9 | NP_938023.1 | |
STING1 | NM_001301738.2 | c.463G>A | p.Val155Met | missense_variant | 5/7 | NP_001288667.1 | ||
STING1 | NM_001367258.1 | c.106G>A | p.Val36Met | missense_variant | 4/7 | NP_001354187.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
STING1 | ENST00000330794.9 | c.463G>A | p.Val155Met | missense_variant | 5/8 | 1 | NM_198282.4 | ENSP00000331288 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000263 AC: 4AN: 152138Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
4
AN:
152138
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.00000398 AC: 1AN: 251308Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 135828
GnomAD3 exomes
AF:
AC:
1
AN:
251308
Hom.:
AF XY:
AC XY:
0
AN XY:
135828
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 6.84e-7 AC: 1AN: 1461864Hom.: 0 Cov.: 31 AF XY: 0.00 AC XY: 0AN XY: 727238
GnomAD4 exome
AF:
AC:
1
AN:
1461864
Hom.:
Cov.:
31
AF XY:
AC XY:
0
AN XY:
727238
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000263 AC: 4AN: 152138Hom.: 0 Cov.: 32 AF XY: 0.0000269 AC XY: 2AN XY: 74316
GnomAD4 genome
AF:
AC:
4
AN:
152138
Hom.:
Cov.:
32
AF XY:
AC XY:
2
AN XY:
74316
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Bravo
AF:
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:7
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
STING-associated vasculopathy with onset in infancy Pathogenic:5
Pathogenic, no assertion criteria provided | clinical testing | Clinical Genetics Laboratory, University Hospital Schleswig-Holstein | Feb 01, 2022 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Victorian Clinical Genetics Services, Murdoch Childrens Research Institute | Jul 17, 2023 | Based on the classification scheme VCGS_Germline_v1.3.4, this variant is classified as Pathogenic. Following criteria are met: 0101 - Gain of function is a known mechanism of disease in this gene and is associated with STING-associated vasculopathy, infantile-onset (MIM#615934). Missense variants were shown to result in reporter activation (PMID: 25029335). (I) 0107 - This gene is associated with autosomal dominant disease. (I) 0115 - Variants in this gene are known to have variable expressivity. Intrafamilial variability has been reported (PMID: 25401470). (I) 0200 - Variant is predicted to result in a missense amino acid change from valine to methionine. (I) 0251 - This variant is heterozygous. (I) 0302 - Variant is present in gnomAD (v3 and v2) <0.001 for a dominant condition (5 heterozygotes, 0 homozygotes). (SP) 0504 - Same amino acid change has been observed in placental mammals. (SB) 0602 - Variant is located in a hotspot region or cluster of pathogenic variants, within the connecter helix loop (DECIPHER, PMID: 32673614). (SP) 0801 - This variant has strong previous evidence of pathogenicity in unrelated individuals. This variant has been reported multiple times as pathogenic, and observed in at least five unrelated individuals with an inflammatory syndrome or infantile onset interstitial lung disease. In four of these individuals, the variant was found to be de novo (ClinVar, PMID: 25029335, PMID: 25401470, PMID: 31705453). (SP) 0903 - This variant has limited evidence for segregation with disease. This variant segregated in three affected members of a single family with a familial inflammatory syndrome (PMID: 25401470). (SP) 1002 - This variant has moderate functional evidence supporting abnormal protein function. Transfected cells showed elevated transcription of IFNB1 and other gene targets (PMID: 25029335, PMID: 25401470). (SP) 1203 - This variant has been shown to be de novo in the proband (parental status confirmed, by trio analysis). (SP) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Sep 19, 2023 | For these reasons, this variant has been classified as Pathogenic. Experimental studies have shown that this missense change affects TMEM173 function (PMID: 25029335, 25401470, 26235147, 28484079). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt TMEM173 protein function. ClinVar contains an entry for this variant (Variation ID: 143862). This missense change has been observed in individual(s) with STING-associated vasculopathy (SAVI) and severe pulmonary disease (PMID: 25029335, 25401470, 27613991). In at least one individual the variant was observed to be de novo. This variant is present in population databases (no rsID available, gnomAD 0.007%). This sequence change replaces valine, which is neutral and non-polar, with methionine, which is neutral and non-polar, at codon 155 of the TMEM173 protein (p.Val155Met). - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Dec 01, 2014 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Oct 31, 2018 | - - |
not provided Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Aug 13, 2015 | The V155M substitution in the TMEM173 gene has been reported previously as both a de novo variant andin a family with multiple affected individuals showing variable clinical features consistent with SALVI (Liuet al., 2014; Jeremiah et al., 2014). Functional studies of the V155M variant indicate it results in gain offunction upregulation of type I interferon production (Jeremiah, et al., 2014). The V155M variant was notobserved in approximately 6,500 individuals of European and African American ancestry in the NHLBIExome Sequencing Project, indicating it is not a common benign variant in these populations. The V155Mvariant is a conservative amino acid substitution, which is at a position that is conserved, but Methioninehas been observed at this position in evolution. In silico analysis predicts this variant is probably damagingto the protein structure/function. Missense variants in nearby residues (V147L and N154S) have beenreported in the Human Gene Mutation Database in association with early onset vasculopathy (Stenson etal., 2014), supporting the functional importance of this region of the protein. We interpret V155M as a pathogenic variant. - |
Pathogenic, criteria provided, single submitter | clinical testing | Center for Genomics, Ann and Robert H. Lurie Children's Hospital of Chicago | Nov 22, 2021 | TMEM173 NM_198282 exon 5 p.Val155Met (c.463G>A): This variant has been reported in the literature in at least 4 individuals with suspected STING related disease (early onset systemic inflammation, cutaneous vasculopathy and pulmonary inflammation), segregating with disease in 2 affected family members and identified as de novo in 2 individuals (Jeremiah 2014 PMID:25401470, Liu 2014 PMID:25029335, Picard 2016 PMID:27613991). This variant is present in 1/15300 African alleles in the Genome Aggregation Database (http://gnomad.broadinstitute.org/). This variant is present in ClinVar (Variation ID:143862). Evolutionary conservation and computational predictive tools suggest that this variant may impact the protein. In vitro functional studies also predict that this variant will impact the protein, with authors proposing a gain of function mechanism (Jeremiah 2014 PMID:25401470, Liu 2014 PMID:25029335, Cerboni 2017 PMID:28484079). In summary, this variant is classified as pathogenic based on the data above. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Uncertain
DANN
Uncertain
DEOGEN2
Benign
T;.
Eigen
Uncertain
Eigen_PC
Uncertain
FATHMM_MKL
Uncertain
D
LIST_S2
Uncertain
D;.
M_CAP
Uncertain
D
MetaRNN
Uncertain
D;D
MetaSVM
Benign
T
MutationAssessor
Uncertain
M;.
MutationTaster
Benign
D
PrimateAI
Uncertain
T
PROVEAN
Benign
N;N
REVEL
Pathogenic
Sift
Pathogenic
D;D
Sift4G
Uncertain
D;D
Polyphen
D;.
Vest4
MutPred
Loss of catalytic residue at V155 (P = 0.0024);Loss of catalytic residue at V155 (P = 0.0024);
MVP
MPC
ClinPred
D
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Varity_R
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at